Status:
COMPLETED
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Coronary Artery Disease
Coronary Heart Disease
Eligibility:
All Genders
45+ years
Phase:
PHASE3
Brief Summary
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal bl...
Eligibility Criteria
Inclusion
- Patients with mixed dyslipidemia
- Qualifying cIMT thickness
Exclusion
- Patients with certain chronic or unstable medical conditions.
- Patients with unstable dose of medications or receiving coumadin, cyclosporine, or certain other medications
- Pregnant or lactating women or women intending to become pregnant
- Patients with diabetes mellitus that is poorly controlled
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
682 Patients enrolled
Trial Details
Trial ID
NCT00616772
Start Date
February 1 2008
End Date
September 1 2012
Last Update
July 2 2018
Active Locations (124)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 6747
Chandler, Arizona, United States, 85225
2
Site Reference ID/Investigator# 7089
Gilbert, Arizona, United States, 85295
3
Site Reference ID/Investigator# 7097
Mesa, Arizona, United States, 85206
4
Site Reference ID/Investigator# 26394
Phoenix, Arizona, United States, 85032